Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
• At least 18 years old and has provided informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.
• Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.
• Measurable per RECIST v1.1
• Adequate organ function (bone marrow, liver, kidney, coagulation).
• Able to take oral medications.